Apimeds Pharmaceuticals US, Inc.
APUS
$2.24
$0.209.80%
AMEX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 370.34% | 34.12% | -48.05% | 179.85% | 7,822.22% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 522.70% | 34.12% | -50.71% | 187.91% | 1,438.85% |
| Operating Income | -522.70% | -34.12% | 50.71% | -187.91% | -1,438.85% |
| Income Before Tax | -492.39% | -35.72% | 45.04% | -202.27% | -1,144.88% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -492.39% | -35.72% | 45.04% | -202.27% | -1,144.88% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -492.39% | -35.72% | 45.04% | -202.27% | -1,144.88% |
| EBIT | -522.70% | -34.12% | 50.71% | -187.91% | -1,438.85% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -351.14% | -35.73% | 55.73% | -65.75% | -505.32% |
| Normalized Basic EPS | -352.11% | -35.90% | 55.76% | -65.41% | -501.69% |
| EPS Diluted | -351.14% | -35.73% | 55.73% | -65.75% | -505.32% |
| Normalized Diluted EPS | -352.11% | -35.90% | 55.76% | -65.41% | -501.69% |
| Average Basic Shares Outstanding | 31.19% | 0.00% | 24.11% | 82.44% | 105.50% |
| Average Diluted Shares Outstanding | 31.19% | 0.00% | 24.11% | 82.44% | 105.50% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |